Published: 12/07/2020 13:14 GMT Kronos Bio Inc (KRON) - Kronos Bio Announces FDA Clearance of Investigational New Drug (ind) Application for Kb-0742, an Oral Cdk9 Inhibitor Targeting Myc-amplified Cancers.
Kronos Bio Inc - Phase 1/2 Clinical Trial to Begin in Q1 of 2021.